GlobalData on MSN23h
Valneva’s chikungunya vaccine wins UK approval
Valneva’s chikungunya vaccine Ixchiq has been greenlit by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) ...
Diabetes drug similar to Ozempic showed no benefits for patients with Parkinson’s disease
A drug for treating diabetes similar to popular weight-loss medicines such as Ozempic did not show any benefits for people ...
chromatographyonline1h
Determining N-Nitrosamines in Pharmaceutical Preparations with LC–MS/MS
A new method has been created for determining N-nitrosamines (NAs) in pharmaceutical preparations using liquid chromatography ...
The American Journal of Managed Care2h
Mirikizumab Demonstrates Superior Maintenance Efficacy in UC Treatment
Mirikizumab showed superior maintenance efficacy over most treatments for ulcerative colitis (UC), according to a network ...
FiercePharma22h
Astellas takes $760M charge, reveals slowdown for eye drug Izervay after regulatory stumbles
Navigating regulatory hurdles in the U.S. and Europe, plus fierce competition from rival Apellis, Astellas’ geographic ...
Eli Lilly and Company: Lilly reports full Q4 2024 financial results and provides 2025 guidance
Revenue in Q4 2024 increased 45% to $13.53 billion driven by volume growth from Mounjaro and Zepbound. Non-incretin revenue(i) grew by 20% compared to Q4 2023. Pipeline ...
NurExone Biologic Inc: NurExone Forms Exo-Top Inc. in the U.S. for Exosome Manufacture and Commercialization
NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (Germany: J90) ("NurExone" or the "Company") is pleased to announce the formation of a U.S.-based ...
Nurexone Forms Exo-Top Inc. In The U.S. For Exosome Manufacture And Commercialization
Exo-Top was established under the jurisdiction of the State of Nevada. Basing Exo-Top in the U.S. offers key advantages, including proximity to strategic partners, access to a robust biopharma ...